Skip to content
Crespine Gel
Menu

One injection instead of a course

Crespine Gel is an injectable gel implant of cross-linked hyaluronic acid for the treatment of osteoarthritis joint pain. It is given as a single 2 ml injection — many other hyaluronic acid preparations require three to five appointments a week apart.

In a prospective cohort study of 111 patients, the improvement in pain and mobility held over twelve months (Suppan et al. 2026). That study had no control group; what it does and does not show is set out on the evidence page.

Is this for me?

What are you looking for?

  • For patients

    How the treatment works, what it costs, which joints it is for, and what the evidence does and does not show.

    Patient information

  • For physicians and clinics

    Composition of both variants, intended purpose, contraindications, published evidence and how to order.

    Professional area

  • For distribution partners

    Exclusive distribution rights — product, evidence, regulatory status and how to apply.

    Distribution partnerships

Two variants

  • Crespine® Gel

    Standard variant, without local anaesthetic.

  • Crespine® Gel +

    Additionally contains the local anaesthetic prilocaine, released slowly from the hyaluronic acid matrix.

Which variant is appropriate is decided by the treating physician. Full composition of both variants

What you should know

Crespine Gel is administered by a physician into the affected joint. The instructions for use list temporary redness, mild swelling, pain and a sensation of heat, which usually resolve within two to five days. Hypersensitivity to hyaluronic acid affects fewer than 1 % of cases.

The intended purpose covers osteoarthritis of the knee or hip joints. Crespine Gel is not supplied directly to private individuals, and this page does not replace a consultation.

Contraindications and adverse effects in full

Manufacturer and certification

Manufactured by BioPolymer GmbH & Co. KG, Walsmühler Str. 18, 19073 Dümmer, Germany. Class III medical device, CE marked under Directive 93/42/EEC, Annex II §4 by notified body CE Certiso Kft. (NB 2409). Quality management certified to ISO 13485:2016, certificate 145211-23-12-15. On the market since 2009. Instructions for use available in DE, EN, FR, IT, ES, PT.